BRPI0910416A2 - conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística - Google Patents

conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística

Info

Publication number
BRPI0910416A2
BRPI0910416A2 BRPI0910416A BRPI0910416A BRPI0910416A2 BR PI0910416 A2 BRPI0910416 A2 BR PI0910416A2 BR PI0910416 A BRPI0910416 A BR PI0910416A BR PI0910416 A BRPI0910416 A BR PI0910416A BR PI0910416 A2 BRPI0910416 A2 BR PI0910416A2
Authority
BR
Brazil
Prior art keywords
hydrazia
divalent
cystic fibrosis
fibrosis transmembrane
conductance regulator
Prior art date
Application number
BRPI0910416A
Other languages
English (en)
Inventor
S Verkman Alan
D Sonawane Nitin
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0910416A2 publication Critical patent/BRPI0910416A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0910416A 2008-04-04 2009-04-03 conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística BRPI0910416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4265108P 2008-04-04 2008-04-04
PCT/US2009/039566 WO2009146144A2 (en) 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
BRPI0910416A2 true BRPI0910416A2 (pt) 2019-09-24

Family

ID=41133847

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910416A BRPI0910416A2 (pt) 2008-04-04 2009-04-03 conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística

Country Status (10)

Country Link
US (1) US20090253799A1 (pt)
EP (1) EP2288592A2 (pt)
JP (1) JP2011516499A (pt)
KR (1) KR20110004413A (pt)
AU (1) AU2009251519A1 (pt)
BR (1) BRPI0910416A2 (pt)
CA (1) CA2718676A1 (pt)
MX (1) MX2010010783A (pt)
TW (1) TW200946129A (pt)
WO (1) WO2009146144A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011074B1 (ru) * 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
KR20100016073A (ko) * 2007-04-02 2010-02-12 인스티튜트 포 원월드 헬스 Ｃｆｔｒ 억제제 화합물 및 이의 용도
EP2279029A2 (en) * 2008-03-25 2011-02-02 The Regents of the University of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264481A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Oxadiazole Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20090264471A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazole Derivatives
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
CA2769847C (en) 2009-08-10 2019-01-08 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
CA3081564A1 (en) * 2017-11-02 2019-05-09 Ube Industries, Ltd. Double-headed protease inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103902T1 (de) * 1982-05-07 1994-04-15 Ciba Geigy Ag Verwendung von chinolinderivaten zum schuetzen von kulturpflanzen.
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
EA011074B1 (ru) * 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor

Also Published As

Publication number Publication date
WO2009146144A2 (en) 2009-12-03
AU2009251519A1 (en) 2009-12-03
KR20110004413A (ko) 2011-01-13
US20090253799A1 (en) 2009-10-08
EP2288592A2 (en) 2011-03-02
WO2009146144A3 (en) 2010-01-28
MX2010010783A (es) 2010-11-12
CA2718676A1 (en) 2009-12-03
TW200946129A (en) 2009-11-16
JP2011516499A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
BRPI0910416A2 (pt) conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística
BRPI0919930A2 (pt) moduladores de regulador de condutância transmembrana de fibrose cística
BRPI1012549A8 (pt) moduladores do regulador da condutância da transmembrana de fibrose cística
DK2252380T3 (da) Skateboard
DK2273984T3 (da) Lipidsammensætning
BRPI0914743A2 (pt) estrutura
BRPI0908269A2 (pt) aplicador
BRPI0910208A2 (pt) umidificador em linha
BRPI0914781A2 (pt) Microbiocidas
BRPI0915047A2 (pt) Composição herbicida
DK2126380T3 (da) Rillet befæstigelseselement
BRPI0908706A2 (pt) Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose cística
BRPI0819633A2 (pt) Métodos para produzir poliolefinas
BRPI0911199A2 (pt) microbiocidas
BRPI0919561A2 (pt) tensionador
BRPI0919170A2 (pt) tensionador
BRPI0921679A2 (pt) composto útil para tratar celulite
BRPI0822264A2 (pt) Dapsona para tratar rosácea
BRPI0919559A2 (pt) baterias
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
DK2323933T3 (da) Stableenhed
BRPI0920470A2 (pt) revestimento betuminoso com desempenho acústico considerável
BRPI0918173A2 (pt) estrutura em degraus
BRPI0911641A2 (pt) unidade estrutural
EP2310262A4 (en) ROGALLO WING NETWORK WITH INTEGRATED RIBS

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.